Drug Profile


Alternative Names: PRT 201

Latest Information Update: 12 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Proteon Therapeutics
  • Class Elastases; Recombinant proteins
  • Mechanism of Action Extracellular matrix protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Vascular disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Vascular disorders
  • Phase I Peripheral arterial disorders

Most Recent Events

  • 10 May 2017 Vonapanitase receives Breakthrough Therapy status for Vascular disorders in USA
  • 18 Apr 2017 Proteon Therapeutics announces intention to submit BLA to US FDA for Vascular disorders in 2019
  • 16 Mar 2017 Proteon Therapeutics has patent protection for vonapanitase in USA, European Union, Australia, China, Hong Kong, Japan, Israel, Mexico, and New Zealand
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top